Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H J Siebelink

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|January 18, 2007
[Acute ST-segment elevation also possible in non-coronary disorders]G A J Jessurun, F Zijlstra, H J Siebelink
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|August 20, 2008
Atrial fibrillation: an unusual causeH J Siebelink, T P Willems, M J W Götte
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 15, 2021
Four guidelines on cardiovascular complications and cardiovascular disease, prognosis and treatment in COVID‑19H J Siebelink, C W Jansen, E Belfroid, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|December 23, 1999
Automated ejection fraction determination from gated myocardial FDG-PET dataA T Willemsen, H J Siebelink, P K Blanksma, et al.
International Journal of Cardiology|June 8, 2000
Detecting hibernating myocardium: how and why?H J Siebelink, S R Underwood, E E van der Wall, et al.
European Journal of Heart Failure|May 30, 2001
Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failureR A de Boer, H J Siebelink, R A Tio, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 16, 2021
Impact of cardiovascular disease and cardiovascular risk factors in hospitalised COVID-19 patientsL S D Jewbali, J Hoogervorst-Schilp, E Belfroid, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 16, 2021
The effects of ACE2 expression mediating pharmacotherapy in COVID-19 patientsR R J van Kimmenade, E Belfroid, J Hoogervorst-Schilp, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 16, 2021
Effect of anticoagulant therapy in COVID-19 patientsR G Tieleman, F A Klok, E Belfroid, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 16, 2021
How often and to what extent do admitted COVID-19 patients have signs of cardiac injury?M A W Habets, H N Sturkenboom, R A Tio, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Nederlands Tijdschrift Voor Geneeskunde|January 18, 2007
[Acute ST-segment elevation also possible in non-coronary disorders]G A J Jessurun, F Zijlstra, H J Siebelink
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|August 20, 2008
Atrial fibrillation: an unusual causeH J Siebelink, T P Willems, M J W Götte
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 15, 2021
Four guidelines on cardiovascular complications and cardiovascular disease, prognosis and treatment in COVID‑19H J Siebelink, C W Jansen, E Belfroid, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|December 23, 1999
Automated ejection fraction determination from gated myocardial FDG-PET dataA T Willemsen, H J Siebelink, P K Blanksma, et al.
International Journal of Cardiology|June 8, 2000
Detecting hibernating myocardium: how and why?H J Siebelink, S R Underwood, E E van der Wall, et al.
European Journal of Heart Failure|May 30, 2001
Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failureR A de Boer, H J Siebelink, R A Tio, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 16, 2021
Impact of cardiovascular disease and cardiovascular risk factors in hospitalised COVID-19 patientsL S D Jewbali, J Hoogervorst-Schilp, E Belfroid, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 16, 2021
The effects of ACE2 expression mediating pharmacotherapy in COVID-19 patientsR R J van Kimmenade, E Belfroid, J Hoogervorst-Schilp, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 16, 2021
Effect of anticoagulant therapy in COVID-19 patientsR G Tieleman, F A Klok, E Belfroid, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 16, 2021
How often and to what extent do admitted COVID-19 patients have signs of cardiac injury?M A W Habets, H N Sturkenboom, R A Tio, et al.
Pageof 2